Lansoprazole is a new type of drug that inhibits gastric acid secretion. It has a significant inhibitory effect on basal gastric acid secretion and gastric acid secretion caused by all stimuli (such as histamine, carbamoylcholine, etc.). It is significantly better than H2 receptor blockers, and the degree of inhibition is significantly dependent on the concentration. Lansoprazole can quickly pass through the parietal cell membrane and turn into sulfenic acid and sulfenyl derivatives under acidic conditions to exert its medicinal effect, and has an inhibitory effect on Helicobacter pylori (Hp). 4 times. It is clinically used for the treatment of duodenal ulcer, gastric ulcer, anastomotic ulcer, reflux esophagitis, Zollinger-Ellison syndrome (Zollinger-Ellison syndrome; gastrinoma), with remarkable curative effect.
Lansoprazole is a substituted benzimidazole derivative, a second proton pump inhibitor. Converted to active sulfenamide derivatives in the acidic environment of gastric parietal cells, which are linked to the sulfhydryl group of H+-K+-(ATP) adenosine triphosphatase (H+-K+-ATPase catalyzes gastric acid secretion the last step of the process), thus inactivating the H+-K+-ATPase and inhibiting both central and peripheral regulated gastric acid secretion. This product is at least as strong as chemicalbook meprazole in inhibiting gastric acid secretion. In vivo studies in animal models show that this product is not as effective as H2 receptor antagonist ranitidine and famotidine in inhibiting gastric acid secretion, but is as effective as omeprazole. Unlike H2 receptor antagonists, this product can inhibit gastric acid secretion during the day and night, whether taken in the morning or in the evening. This product can also reduce gastric acid secretion and inhibit the secretion and activity of pepsin. This product can remove Campylobacter pylori (a bacterium that causes recurrence of peptic ulcers) on the gastric mucosa.
){kind=link}